CoChat

A GLP-1/GIP/Gcg receptor triagonist improves memory behavior, as well as synaptic transmission, neuronal excitability and Ca2+ homeostasis in 3xTg-AD mice

Li, Tian, Jiao, Juan-Juan, Su, Qiang, Hölscher, Christian, Zhang, Jun, Yan, Xu-Dong, Zhao, Hui-Min, Cai, Hong-Yan, Qi, Jin-Shun · 2020 · Neuropharmacology
Cited by 36

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.

Abstract

Alzheimer's disease (AD) is a progressively neurodegenerative disorder, which seriously affects human health and cannot be stopped by current treatments. Type 2 diabetes mellitus (T2DM) is a risk factor for AD. Our recent studies reported the neuroprotective effects of a GLP-1/GIP/Glucagon receptor triagonist (Triagonist), a novel unimolecular anti-diabetic drug, in cognitive and pathological improvements of 3xTg-AD mice. However, the detailed electrophysiological and molecular mechanisms underlying neuroprotection remain unexplored. The present study investigated the underlying electrophysiological and molecular mechanisms further by using whole-cell patch clamp techniques. Our results revealed that chronic Triagonist treatment effectively reduced working memory and reference memory errors of 3xTg-AD mice in a radial maze test. In addition, the Triagonist increased spontaneous excitatory synaptic activities, differentially modulated voltage- and chemically-gated Ca2+ flux, and reduced the over-excitation of pyramidal neurons in hippocampal slices of 3xTg-AD mice. In addition, chronic Triagonist treatment also up-regulated the expression levels of synaptophysin and PSD-95 in the hippocampus of 3xTg-AD mice. These results indicate that the Triagonist could improve memory formation, as well as synaptic transmission, Ca2+ balance, and neuronal excitability in 3xTg-AD mice. These neuroprotective effects of Triagonist may be involved in the up-regulation of synaptophysin and PSD-95. Therefore, the study suggests that multi-receptor agonists might be a novel therapeutic strategy for the treatment of AD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.neuropharm.2020.108042

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 30 references

Research works printed but not linked: 74

  1. Arsenault, 2011, DHA improves cognition and prevents dysfunction of entorhinal cortex neurons in 3xTg-AD mice, PloS One, 6, e17397, 10.1371/journal.pone.0017397 · DOI · Paper page
  2. Becher, 1999, The synaptophysin-synaptobrevin complex: a hallmark of synaptic vesicle maturation, J. Neurosci., 19, 1922, 10.1523/JNEUROSCI.19-06-01922.1999 · DOI · Paper page
  3. Bliss, 1993, A synaptic model of memory: long-term potentiation in the hippocampus, Nature, 361, 31, 10.1038/361031a0 · DOI · Paper page
  4. Busche, 2008, Clusters of hyperactive neurons near amyloid plaques in a mouse model of Alzheimer's disease, Science, 321, 1686, 10.1126/science.1162844 · DOI · Paper page
  5. Calhoun, 1996, Comparative evaluation of synaptophysin-based methods for quantification of synapses, J. Neurocytol., 25, 821, 10.1007/BF02284844 · DOI · Paper page
  6. Celone, 2006, Alterations in memory networks in mild cognitive impairment and Alzheimer's disease: an independent component analysis, J. Neurosci., 26, 10222, 10.1523/JNEUROSCI.2250-06.2006 · DOI · Paper page
  7. Chiu, 2008, Insulin receptor signaling regulates synapse number, dendritic plasticity, and circuit function in vivo, Neuron, 58, 708, 10.1016/j.neuron.2008.04.014 · DOI · Paper page
  8. Clark, 2015, Alterations in synaptic plasticity coincide with deficits in spatial working memory in presymptomatic 3xTg-AD mice, Neurobiol. Learn. Mem., 125, 152, 10.1016/j.nlm.2015.09.003 · DOI · Paper page
  9. Cork, 2015, Distribution and characterisation of Glucagon-like peptide-1 receptor expressing cells in the mouse brain, Mol Metab, 4, 718, 10.1016/j.molmet.2015.07.008 · DOI · Paper page
  10. Counts, 2014, Synaptic gene dysregulation within hippocampal CA1 pyramidal neurons in mild cognitive impairment, Neuropharmacology, 79, 172, 10.1016/j.neuropharm.2013.10.018 · DOI · Paper page
  11. Cui, 2014, Amyloid precursor protein mutation disrupts reproductive experience-enhanced normal cognitive development in a mouse model of Alzheimer's disease, Mol. Neurobiol., 49, 103, 10.1007/s12035-013-8503-x · DOI
  12. D'Amelio, 2012, Brain excitability and connectivity of neuronal assemblies in Alzheimer's disease: from animal models to human findings, Prog. Neurobiol., 99, 42, 10.1016/j.pneurobio.2012.07.001 · DOI
  13. Daschil, 2015, L-type calcium channel blockers and substance P induce angiogenesis of cortical vessels associated with beta-amyloid plaques in an Alzheimer mouse model, Neurobiol. Aging, 36, 1333, 10.1016/j.neurobiolaging.2014.12.027 · DOI · Paper page
  14. Demuro, 2005, Calcium dysregulation and membrane disruption as a ubiquitous neurotoxic mechanism of soluble amyloid oligomers, J. Biol. Chem., 280, 17294, 10.1074/jbc.M500997200 · DOI · Paper page
  15. Dewachter, 2009, Deregulation of NMDA-receptor function and down-stream signaling in APP[V717I] transgenic mice, Neurobiol. Aging, 30, 241, 10.1016/j.neurobiolaging.2007.06.011 · DOI
  16. Ehses, 2003, Glucose-dependent insulinotropic polypeptide promotes beta-(INS-1) cell survival via cyclic adenosine monophosphate-mediated caspase-3 inhibition and regulation of p38 mitogen-activated protein kinase, Endocrinology, 144, 4433, 10.1210/en.2002-0068 · DOI · Paper page
  17. El-Husseini Ael, 2002, Synaptic strength regulated by palmitate cycling on PSD-95, Cell, 108, 849, 10.1016/S0092-8674(02)00683-9 · DOI · Paper page
  18. Ferreira, 2012, Amyloid beta peptide 1-42 disturbs intracellular calcium homeostasis through activation of GluN2B-containing N-methyl-d-aspartate receptors in cortical cultures, Cell Calcium, 51, 95, 10.1016/j.ceca.2011.11.008 · DOI · Paper page
  19. Francesco, 2015, Altered intrinsic excitability of hippocampal CA1 pyramidal neurons in aged PDAPP mice, Front. Cell. Neurosci., 9, 372
  20. Frazzini, 2016, Altered Kv2.1 functioning promotes increased excitability in hippocampal neurons of an Alzheimer's disease mouse model, Cell Death Dis., 7, e2100, 10.1038/cddis.2016.18 · DOI · Paper page
  21. Freiherr, 2013, Intranasal insulin as a treatment for Alzheimer's disease: a review of basic research and clinical evidence, CNS Drugs, 27, 505, 10.1007/s40263-013-0076-8 · DOI · Paper page
  22. Gavello, 2018, Early alterations of hippocampal neuronal firing induced by Abeta42, Cerebr. Cortex, 28, 433
  23. Gilman, 2003, Glucagon-like peptide 1 modulates calcium responses to glutamate and membrane depolarization in hippocampal neurons, J. Neurochem., 87, 1137, 10.1046/j.1471-4159.2003.02073.x · DOI · Paper page
  24. Girones, 2004, N epsilon-carboxymethyllysine in brain aging, diabetes mellitus, and Alzheimer's disease, Free Radic. Biol. Med., 36, 1241, 10.1016/j.freeradbiomed.2004.02.006 · DOI
  25. Glasgow, 2018, Activity-dependent netrin-1 secretion drives synaptic insertion of GluA1-containing AMPA receptors in the Hippocampus, Cell Rep., 25, 168, 10.1016/j.celrep.2018.09.028 · DOI · Paper page
  26. Glass, 2010, Mechanisms underlying inflammation in neurodegeneration, Cell, 140, 918, 10.1016/j.cell.2010.02.016 · DOI · Paper page
  27. Hölscher, 2016, Glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide analogues as novel treatments for Alzheimer's and Parkinson's disease, Cardiovasc. Endocrinol., 5, 93, 10.1097/XCE.0000000000000087 · DOI
  28. Hölscher, 2018, Novel dual GLP-1/GIP receptor agonists show neuroprotective effects in Alzheimer's and Parkinson's disease models, Neuropharmacology, 136, 251, 10.1016/j.neuropharm.2018.01.040 · DOI · Paper page
  29. Hardy, 2002, The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics, Science, 297, 353, 10.1126/science.1072994 · DOI · Paper page
  30. Hollmann, 1994, Cloned glutamate receptors, Annu. Rev. Neurosci., 17, 31, 10.1146/annurev.ne.17.030194.000335 · DOI · Paper page
  31. Hoosein, 1984, Identification of glucagon receptors in rat brain, Proc. Natl. Acad. Sci. U. S. A., 81, 4368, 10.1073/pnas.81.14.4368 · DOI · Paper page
  32. Hu, 2017, Overexpression of EphB2 in hippocampus rescues impaired NMDA receptors trafficking and cognitive dysfunction in Alzheimer model, Cell Death Dis., 8, e2717, 10.1038/cddis.2017.140 · DOI · Paper page
  33. Hu, 2011, BDNF-induced increase of PSD-95 in dendritic spines requires dynamic microtubule invasions, J. Neurosci., 31, 15597, 10.1523/JNEUROSCI.2445-11.2011 · DOI · Paper page
  34. Hyman, 2014, Tau propagation, different tau phenotypes, and prion-like properties of tau, Neuron, 82, 1189, 10.1016/j.neuron.2014.06.004 · DOI
  35. Jiao, 2017, GLP-1/GIP/Gcg receptor Triagonist improves the cognitive behaviors in triple-transgenic mice of Alzheimer's disease, Acta Physiol. Sin., 69, 135
  36. Kaplan, 1994, Gastric inhibitory polypeptide (GIP) binding sites in rat brain, Peptides, 15, 297, 10.1016/0196-9781(94)90016-7 · DOI
  37. Kim, 2008, Glucose-dependent insulinotropic polypeptide-mediated up-regulation of beta-cell antiapoptotic Bcl-2 gene expression is coordinated by cyclic AMP (cAMP) response element binding protein (CREB) and cAMP-responsive CREB coactivator 2, Mol. Cell Biol., 28, 1644, 10.1128/MCB.00325-07 · DOI · Paper page
  38. Kim, 2005, J. Biol. Chem., 280, 22297, 10.1074/jbc.M500540200 · DOI · Paper page
  39. Lee, 2011, Insulin promotes dendritic spine and synapse formation by the PI3K/Akt/mTOR and Rac1 signaling pathways, Neuropharmacology, 61, 867, 10.1016/j.neuropharm.2011.06.003 · DOI · Paper page
  40. Lennox, 2015, Effects of glucose-dependent insulinotropic polypeptide receptor knockout and a high-fat diet on cognitive function and hippocampal gene expression in mice, Mol. Med. Rep., 12, 1544, 10.3892/mmr.2015.3447 · DOI
  41. Li, 2018, A novel GLP-1/GIP/Gcg triagonist reduces cognitive deficits and pathology in the 3xTg mouse model of Alzheimer's disease, Hippocampus, 28, 358, 10.1002/hipo.22837 · DOI · Paper page
  42. Li, 2017, Real-time measurement of Ca2+ flux in hippocampal slice with non-invasive microtest technique, Acta Physiol. Sin., 69, 467
  43. Lourenco, 2013, TNF-alpha mediates PKR-dependent memory impairment and brain IRS-1 inhibition induced by Alzheimer's beta-amyloid oligomers in mice and monkeys, Cell Metabol., 18, 831, 10.1016/j.cmet.2013.11.002 · DOI · Paper page
  44. Mark, 1995, Amyloid beta-peptide impairs ion-motive ATPase activities: evidence for a role in loss of neuronal Ca2+ homeostasis and cell death, J. Neurosci., 15, 6239, 10.1523/JNEUROSCI.15-09-06239.1995 · DOI · Paper page
  45. Mayo, 2003, International Union of Pharmacology. XXXV. The glucagon receptor family, Pharmacol. Rev., 55, 167, 10.1124/pr.55.1.6 · DOI · Paper page
  46. Mittal, 2016, Shared links between type 2 diabetes mellitus and Alzheimer's disease: a review, Diabetes Metab Syndr, 10, S144, 10.1016/j.dsx.2016.01.021 · DOI
  47. Miyakawa, 1996, Radial maze performance, open-field and elevated plus-maze behaviors in Fyn-kinase deficient mice: further evidence for increased fearfulness, Brain Res Mol Brain Res, 37, 145, 10.1016/0169-328X(95)00300-H · DOI
  48. Mota, 2014, Dysfunctional synapse in Alzheimer's disease - a focus on NMDA receptors, Neuropharmacology, 76, 16, 10.1016/j.neuropharm.2013.08.013 · DOI · Paper page
  49. Newcomer, 2000, NMDA receptor function, memory, and brain aging, Dialogues Clin. Neurosci., 2, 219, 10.31887/DCNS.2000.2.3/jnewcomer · DOI · Paper page
  50. Oddo, 2003, Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction, Neuron, 39, 409, 10.1016/S0896-6273(03)00434-3 · DOI · Paper page
  51. Pancani, 2009, Distinct modulation of voltage-gated and ligand-gated Ca2+ currents by PPAR-gamma agonists in cultured hippocampal neurons, J. Neurochem., 109, 1800, 10.1111/j.1471-4159.2009.06107.x · DOI · Paper page
  52. Putcha, 2011, Hippocampal hyperactivation associated with cortical thinning in Alzheimer's disease signature regions in non-demented elderly adults, J. Neurosci., 31, 17680, 10.1523/JNEUROSCI.4740-11.2011 · DOI · Paper page
  53. Rönicke, 2011, Early neuronal dysfunction by amyloid beta oligomers depends on activation of NR2B-containing NMDA receptors, Neurobiol. Aging, 32, 2219, 10.1016/j.neurobiolaging.2010.01.011 · DOI · Paper page
  54. Satoh, 2007, Extracellular signal-regulated kinase 2 (ERK2) knockdown mice show deficits in long-term memory; ERK2 has a specific function in learning and memory, J. Neurosci., 27, 10765, 10.1523/JNEUROSCI.0117-07.2007 · DOI · Paper page
  55. Shoelson, 2006, Inflammation and insulin resistance, J. Clin. Invest., 116, 1793, 10.1172/JCI29069 · DOI · Paper page
  56. Stover, 2012, Lifespan developmental study of the 3xTg-AD mouse model of Alzheimer's disease: the effect of maternal genotype on later life cognitive performance, Dev. Psychobiol., 54
  57. Stutzmann, 2003, Ca2+ signaling in mouse cortical neurons studied by two-photon imaging and photoreleased inositol triphosphate, J. Neurosci., 23, 758, 10.1523/JNEUROSCI.23-03-00758.2003 · DOI · Paper page
  58. Sudhof, 1987, A synaptic vesicle protein with a novel cytoplasmic domain and four transmembrane regions, Science, 238, 1142, 10.1126/science.3120313 · DOI · Paper page
  59. Tai, 2018, Neuroprotective effects of a triple GLP-1/GIP/glucagon receptor agonist in the APP/PS1 transgenic mouse model of Alzheimer's disease, Brain Res., 1678, 64, 10.1016/j.brainres.2017.10.012 · DOI
  60. Tian, 2016, Resveratrol improves cognitive impairment by regulating apoptosis and synaptic plasticity in streptozotocin-induced diabetic rats, Cell. Physiol. Biochem., 40, 1670, 10.1159/000453216 · DOI · Paper page
  61. Tu, 2014, Oligomeric Abeta-induced synaptic dysfunction in Alzheimer's disease, Mol. Neurodegener., 9, 48, 10.1186/1750-1326-9-48 · DOI · Paper page
  62. Turrigiano, 2004, Homeostatic plasticity in the developing nervous system, Nat. Rev. Neurosci., 5, 97, 10.1038/nrn1327 · DOI · Paper page
  63. Ueda, 1997, Amyloid beta protein potentiates Ca2+ influx through L-type voltage-sensitive Ca2+ channels: a possible involvement of free radicals, J. Neurochem., 68, 265, 10.1046/j.1471-4159.1997.68010265.x · DOI · Paper page
  64. Unger, 1998, Insulin receptors and signal transduction proteins in the hypothalamo-hypophyseal system: a review on morphological findings and functional implications, Histol. Histopathol., 13, 1215
  65. Verma, 2018, Targeting glucose-dependent insulinotropic polypeptide receptor for neurodegenerative disorders, Expert Opin. Ther. Targets, 22, 615, 10.1080/14728222.2018.1487952 · DOI · Paper page
  66. Wang, 2014, L-type Ca2+ currents at CA1 synapses, but not CA3 or dentate granule neuron synapses, are increased in 3xTgAD mice in an age-dependent manner, Neurobiol. Aging, 35, 88, 10.1016/j.neurobiolaging.2013.07.007 · DOI · Paper page
  67. Werther, 1987, Localization and characterization of insulin receptors in rat brain and pituitary gland using in vitro autoradiography and computerized densitometry, Endocrinology, 121, 1562, 10.1210/endo-121-4-1562 · DOI · Paper page
  68. Wiedenmann, 1985, Identification and localization of synaptophysin, an integral membrane glycoprotein of Mr 38,000 characteristic of presynaptic vesicles, Cell, 41, 1017, 10.1016/S0092-8674(85)80082-9 · DOI · Paper page
  69. Yaka, 2003, Pituitary adenylate cyclase-activating polypeptide (PACAP(1-38)) enhances N-methyl-D-aspartate receptor function and brain-derived neurotrophic factor expression via RACK1, J. Biol. Chem., 278, 9630, 10.1074/jbc.M209141200 · DOI · Paper page
  70. Yamamoto, 2002, A distinct form of calcium release down-regulates membrane excitability in neocortical pyramidal cells, Neuroscience, 109, 665, 10.1016/S0306-4522(01)00486-9 · DOI
  71. Yarchoan, 2014, Repurposing diabetes drugs for brain insulin resistance in Alzheimer disease, Diabetes, 63, 2253, 10.2337/db14-0287 · DOI · Paper page
  72. Zhang, 2011, The AAA+ ATPase Thorase regulates AMPA receptor-dependent synaptic plasticity and behavior, Cell, 145, 284, 10.1016/j.cell.2011.03.016 · DOI · Paper page
  73. Zhang, 2009, Amyloid β-protein differentially affects NMDA receptor- and GABAA receptor-mediated currents in rat hippocampal CA1 neurons, Prog. Nat. Sci., 19, 963, 10.1016/j.pnsc.2008.11.006 · DOI
  74. Zhang, 2016, A novel acetylcholinesterase inhibitor and calcium channel blocker SCR-1693 improves Abeta25-35-impaired mouse cognitive function, Psychopharmacology, 233, 599, 10.1007/s00213-015-4133-5 · DOI

Cited by

See all 36

Metadata

Authors
Li, T., Jiao, J.-J., Su, Q., Hölscher, C., Zhang, J., Yan, X.-D., Zhao, H.-M., Cai, H.-Y., & Qi, J.-S.
Venue
Neuropharmacology
Publisher
Elsevier BV
Published
2020-06
Volume
170
Pages
108042
ISSN
0028-3908 (ISSN-L)
OpenAlex
W3009658421
Cited by
36
References
30
FWCI
3.02
Type
journal article
Language
en
Open access
closed
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)
Funders
National Natural Science Foundation of China

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A GLP-1/GIP/Gcg receptor triagonist improves memory behavior, as well as synaptic transmission, neuronal excitability and Ca2+ homeostasis in 3xTg-AD mice. https://app.cochat.ai/papers/10.1016/j.neuropharm.2020.108042
The paper
Li, T., Jiao, J.-J., Su, Q., Hölscher, C., Zhang, J., Yan, X.-D., Zhao, H.-M., Cai, H.-Y., & Qi, J.-S. (2020). A GLP-1/GIP/Gcg receptor triagonist improves memory behavior, as well as synaptic transmission, neuronal excitability and Ca2+ homeostasis in 3xTg-AD mice. Neuropharmacology. https://doi.org/10.1016/j.neuropharm.2020.108042

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.